Emerging investigations on retatrutides, a dual stimulant for GLP-1 and glucose-dependent insulinotropic polypeptide, suggest promising findings in managing obesity and type 2 diabetes. Early evidence from clinical trials show considerable diminutions in body weight and enhanced glucose regulatio